Biotech Values

[turtlepower]

Slides 8 and 10 contain the safety data for 387.

http://www.ymbiosciences.com/upload_files/CYT387_pres_ASH2010_Mayo.pdf

Slide 10 compares cyt387 with 18424. The slide appears to compare treatment with 424 after a median duration of 14 months with 387 after a median duration of about 5 months and highlights that the % of anemia incidents for 424 is 3x of 387. The percentage of thrombocytopenia incidents is about 40% higher for 387. Also when comparing treatment related withdrawals at almost similar treatment durations, from the ASH presentation in 2008 it appears about 17/134 patients withdrew from the 424 study after a median treatment duration of about 7 months. As of todays presentation there are 0 withdrawals out of 60 for 387.

387 is also a QD oral drug.